The United States health protection agency FDA is grappling with if and when to inject a third shot of single-dose Johnson & Johnson coronavirus jab, while the latest research released on Oct. 13 raises the anticipation that injecting a different jab as the third shot might be more effective.

J&J COVID vaccine receivers are better off getting an additional dose from Moderna or Pfizer, a highly anticipated American study recommended yesterday. The National Institute of Health (NIH) research mix-and-match coronavirus jabs included around 458 volunteers who have got one of the three regimens presently available in America; Pfizer, J&J, or Moderna’s. However, the research has not been analyzed, which looks at whether there are any advantages or drawbacks to using different third doses.

The study of the COVID-19 vaccines from Pfizer, Moderna, and J&J currently authorized in the US showed that using different types of shots as boosters generally appeared to produce a comparable or higher antibody response than using the same type. pic.twitter.com/MDbAuXm4rC

— ONE News PH (@onenewsph) October 14, 2021

Furthermore, in an online review, Food and Drug Administration scientists did not reach a company conclusion regarding whether there is enough evidence for Janssen booster doses, mentioning shortcomings with the firm’s data and less information on effectiveness against more virulent Delta variant of SARS-CoV-2.

Vaccine Mix-and-Match Doesn’t Matter, Boosts Immunity

The latest study finds that if we receive the J&J vaccine as our first COVID dose, a booster shot of either Pfizer or Moderna jab apparently could generate a robust immune response than the second shot of Janssen’s. And if we begin with either Moderna or Pfizer, it likely does not matter that much, as long as we receive one of the two messenger-RNA jabs as a third dose.

The US FDA review comes before meetings on Oct. 14 and 15, when the agency’s advisory panel will approve whether to back additional shots of both Moderna and J&J vaccines. That is a move in the administration’s jab review process. Moreover, in the coming week, the FDA will make a conclusive remark on approving those additional doses, and then the US CDC will discuss the booster-eligible Americans.

In September, American regulators approved third or booster shots of the COVID jab developed by Pfizer-BioNTech to an extensive array of US citizens, including the elderly, adults with compromised medical conditions, and those who toil in high-risk areas, such as grocery and health employees.